Results 181 to 190 of about 125,339 (239)

Twenty‐Four Month Outcomes From a Real‐World Telehealth Obesity Treatment Clinic Using Obesity Medications

Obesity, EarlyView.
ABSTRACT Objective Antiobesity medications (AOMs) are indicated for long‐term use; however, evidence of their real‐world long‐term efficacy is limited. This study describes clinical outcomes from 18‐ and 24‐month use of AOMs in a telemedicine weight management clinic.
Kathleen R. Ruddiman, Young‐Rock Hong, Jamy Ard, Rebecca Jones, Adam Medcalf, Gary D. Foster, Jamil Alkhaddo, Michelle Cardel   +7 more
wiley   +1 more source

HMGCR and Rosuvastatin Regulates GLP-1 Secretion and Expression-A Translational Study.

J Clin Endocrinol Metab
Miskelly MG, Lindqvist A, Jujić A, Hamilton A, Cowan E, Raikundalia S, Dutius Andersson AM, Nergård BJ, Del Giudice R, Kryvokhyzha D, Nilsson PM, Holst JJ, Torekov SS, Lagerstedt JO, Gomez MF, Eliasson L, Mulder H, Hedenbro J, Magnusson M, Wierup N.   +19 more
europepmc   +1 more source

Weight Loss With GLP‐1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta‐Analysis

Obesity, EarlyView.
ABSTRACT Objective Two glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) (semaglutide and liraglutide) and one dual agonist (tirzepatide) are FDA‐approved for weight loss in adults with obesity without type 2 diabetes mellitus. This systematic review and network meta‐analysis aims to compare the efficacy of these agents against each other.
Michael Lim, Pooja Gokhale, Akwasi Akosah, Lorenzo Villa‐Zapata   +3 more
wiley   +1 more source

Crystallization and 1.6 Å resolution crystal structure of an acylated GLP-1/GIP analogue peptide. [PDF]

Acta Crystallogr F Struct Biol Commun
Mitchell HM, Nocek B, Guinn EJ, Heng JYY.   +3 more
europepmc   +1 more source

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

Obesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone, Mary Playdon, Stephen D. Hursting, Aik Choon Tan   +3 more
wiley   +1 more source

Time-Related Biases in Observational Studies of GLP-1 Agonists and Cancer Risk. [PDF]

J Diabetes
Lu F.
europepmc   +1 more source

Primary cilia regulate GLP-1 signaling in pancreatic β cells. [PDF]

Mol Metab
Melena I, Jo JH, Townsend SE, DiGruccio SA, Dong X, Zhu L, Campbell J, Hughes JW.   +7 more
europepmc   +1 more source

Parental Communication With Children Around Obesity Management Medications, Weight Loss, and Health Behavior Change

Obesity, EarlyView.
ABSTRACT Objective This study aimed to describe parental communication with children around obesity management medications (OMMs) and child, parent, and family factors associated with communication. Methods Parents (N = 211; 80% mothers; 89% White) prescribed OMMs at a medical center participated in a survey about communication with children about OMM ...
Keeley J. Pratt, Selena Gonzlez‐Jordan, Sabrena F. Noria, Joseph A. Skelton   +3 more
wiley   +1 more source

Med14 phosphorylation shapes genomic response to GLP-1 agonists. [PDF]

Proc Natl Acad Sci U S A
Van de Velde S, Yu J, Garrett Evensen K, Pakhlevanyan E, Williams AE, Shaw RJ, Montminy M.   +6 more
europepmc   +1 more source

Monogenic and syndromic obesity in children: Clinical recognition, genetics, and precision management

Pediatric Investigation, EarlyView.
Monogenic and syndromic obesity in children often arises from defects in the leptin–melanocortin pathway. Understanding these rare genetic causes not only clarifies mechanisms of appetite regulation but also enables precision therapies, offering hope beyond lifestyle interventions.
Hadel Khalil, Eugene Feigin, Hussein Zaitoon   +2 more
wiley   +1 more source